![]() |
|
|
Vol. 59, Issue 2, 254-262, February 2001
Laboratory of Molecular and Cellular Toxicology, Institute of
Toxicology, College of Medicine, National Taiwan University, Taipei,
Taiwan (S.-G.S., M.-L.K.); and Division of Cancer Research, National
Health Research Institute, Taipei, Taiwan (S.-E.C.)
Paclitaxel is a novel anticancer drug that has demonstrated efficacy
toward treating several malignant tumor types. Here, we demonstrate
that c-Jun NH2-terminal kinase (JNK), but not p38 mitogen-activated protein kinase or extracellular signal-regulated kinase 1/2, was persistently activated by paclitaxel or other microtubule-damaging agents within human leukemia HL-60 cells. Overexpression of a dominant-negative mutant, mitogen-activated protein
kinase kinase 1 (MEKK1-DN) or treatment with JNK-specific antisense
oligonucleotide prevented paclitaxel-induced JNK activation, Bcl-2
phosphorylation and apoptosis. Furthermore, we found that the
full-length MEKK1 was cleaved to a 91-kDa carboxyl-terminal fragment at
the earlier time of apoptosis induced by microtubule-damaging agents.
This cleavage, however, occurred consistently with JNK activation and
Bcl-2 phosphorylation, but preceded DNA fragmentation in cells in
response to paclitaxel activity. The caspase inhibitor Ac-Asp-Glu-Val-Asp-CHO (DEVD-CHO), but not Ac-Tyr-Val-Ala-Asp-CHO (Ac-YVAD-CHO), effectively blocked MEKK1 cleavage, JNK activation, Bcl-2 phosphorylation, and subsequent apoptosis. Subcellular
fractionation revealed that the 91-kDa C-terminal MEKK1 fragment was
translocated to cytosol. Notably, the MEKK1 fragment could be
coimmunoprecipitated with anti-JNK antibodies, suggesting that a
signaling complex of C-terminal MEKK1/stress-activated protein
kinase/extracellular-signal regulated kinase 1/JNK formed during
apoptosis induced by microtubule-damaging agents. Taken together, our
results suggest that disruption of cytoarchitecture by paclitaxel
triggers a novel apoptosis-signaling pathway, wherein an active
DEVD-directed caspase (DEVDase) initially cleaves MEKK1to generate a
proapoptotic kinase fragment that is able to activate JNK and
subsequent Bcl-2 phosphorylation, finally eliciting cell death.
This article has been cited by other articles:
![]() |
J.-L. Su, M.-T. Lin, C.-C. Hong, C.-C. Chang, S.-G. Shiah, C.-W. Wu, S.-T. Chen, Y.-P. Chau, and M.-L. Kuo Resveratrol induces FasL-related apoptosis through Cdc42 activation of ASK1/JNK-dependent signaling pathway in human leukemia HL-60 cells Carcinogenesis, January 1, 2005; 26(1): 1 - 10. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Mc Gee, L. M. Greene, S. Ledwidge, G. Campiani, V. Nacci, M. Lawler, D. C. Williams, and D. M. Zisterer Selective Induction of Apoptosis by the Pyrrolo-1,5-benzoxazepine 7-[{Dimethylcarbamoyl}oxy]-6-(2-naphthyl)pyrrolo-[2,1-d] (1,5)-benzoxazepine (PBOX-6) in Leukemia Cells Occurs via the c-Jun NH2-Terminal Kinase-Dependent Phosphorylation and Inactivation of Bcl-2 and Bcl-XL J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 1084 - 1095. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. M. Pushkarev, D. V. Starenki, V. A. Saenko, H. Namba, J. Kurebayashi, M. D. Tronko, and S. Yamashita Molecular Mechanisms of the Effects of Low Concentrations of Taxol in Anaplastic Thyroid Cancer Cells Endocrinology, July 1, 2004; 145(7): 3143 - 3152. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. E. Brown and J. L. Boyle Mesenchymal Chondrosarcoma: Molecular Characterization by a Proteomic Approach, with Morphogenic and Therapeutic Implications Ann. Clin. Lab. Sci., April 1, 2003; 33(2): 131 - 141. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Kwan, J. Burnside, T. Kurosaki, and G. Cheng MEKK1 Is Essential for DT40 Cell Apoptosis in Response to Microtubule Disruption Mol. Cell. Biol., November 1, 2001; 21(21): 7183 - 7190. [Abstract] [Full Text] [PDF] |
||||